Author

J. E. Maxson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:differential expression· 5 Research Focus:cell type annotation· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:gene regulatory network inference· 3 Organism:mouse· 3

Frequent Co-Authors

T. P. Braun· 6 shared B. J. Druker· 5 shared B. M. Smith· 5 shared Z. Schonrock· 4 shared C. Coblentz· 3 shared D. J. Coleman· 3 shared J. Estabrook· 3 shared S. A. Carratt· 3 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

T. P. Braun

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Mutational screens highlight glycosylation as a modulator of CSF3R activity

M. J. Hollander, S. A. Malaker, I. Perez, J. E. Maxson, J. R. Cochran, C. R. Bertozzi

The paper identifies glycosylation sites as critical for CSF3R activity and shows that mutations at these sites can lead to ligand-independent cell growth in chronic neutrophilic leukemia.

bioRxiv · Aug 1, 2022 · PreprintBiochemistry

Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

W. M. Yashar, B. M. Smith, D. J. Coleman, J. VanCampen, G. Kong, J. Macaraeg, J. Estabrook, E. Demir, N. Long, D. Bottomly, S. K. McWeeney, J. W. Tyner, B. J. Druker, J. E. Maxson, T. P. Braun

This study shows that combining FLT3 and LSD1 inhibitors synergistically kills FLT3-mutant AML cells by disrupting the MYC super-enhancer complex.

bioRxiv · Jan 17, 2022 · PreprintCancer Biology

Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms

S. A. Carratt, G. L. Kong, B. M. Smith, Z. Schonrock, L. Maloney, A. Baris, B. J. Druker, T. P. Braun, J. E. Maxson

This study shows that mutant SETBP1 promotes aggressive myeloproliferative neoplasms by upregulating Myc and its target genes, which can be reversed by epigenetic drugs.

bioRxiv · Nov 4, 2021Cancer Biology

PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia

B. M. Smith, J. VanCampen, G. L. Kong, W. Yashar, Y. H. Tsang, W. Horton, D. J. Coleman, J. Estabrook, T. A. Lusardi, G. B. Mills, B. J. Druker, J. E. Maxson, T. P. Braun

This paper shows that combining KIT and LSD1 inhibitors synergistically kills KIT-mutant AML cells by reducing MYC expression and inactivating PI3K/AKT signaling, supporting a clinical trial.

bioRxiv · Aug 24, 2021 · PreprintCancer Biology

Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia

S. A. Carratt, T. P. Braun, C. Coblentz, Z. Schonrock, R. Callahan, B. M. Smith, L. Maloney, A. Foley, J. E. Maxson

This study shows that SETBP1 mutations enhance NRAS-driven MAPK signaling in leukemia, making cells sensitive to MEK inhibitor trametinib.

bioRxiv · Feb 1, 2021Cancer Biology

ASXL1 Directs Neutrophilic Differentiation via Modulation of MYC and RNA Polymerase II.

T. P. Braun, J. Estabrook, L. Darmusey, D. J. Coleman, Z. Schonrock, B. M. Smith, T. Enright, A. Taherinasab, C. Coblentz, W. Yashar, R. Callahan, H. Mohammed, B. J. Druker, T. Lusardi, J. E. Maxson

This study identifies ASXL1's role in neutrophil differentiation by modulating MYC and RNA Polymerase II, showing its impact on granulocyte maturation and myeloid malignancies.

bioRxiv · Sep 14, 2020 · PreprintCancer Biology

Myeloid Lineage Enhancers Drive Oncogene Synergy in CEBPA/CSF3R Mutant Acute Myeloid Leukemia

T. P. Braun, M. Okhovat, C. Coblentz, S. A. Carratt, A. Foley, Z. Schonrock, K. Nevonen, B. Davis, B. Garcia, D. LaTocha, B. R. Weeder, M. R. Grzadkowski, J. C. Estabrook, H. G. Manning, K. Watanabe-Smith, , J. E. Maxson

The paper identifies mutation synergy between CSF3R and CEBPA in AML, showing their interaction at myeloid lineage enhancers and the requirement of CEBPA mutations as an initial event.

bioRxiv · May 15, 2019Cancer Biology